T. Buclin

Discipline

Psychologie (13) Sociologie (3) Economies et finances (2) Histoire, Philosophie et Sociologie des sciences (1) Education (1) Anthropologie biologique (1)

Type de document

Articles (82) Colloques et conférences (13) Recensions (12) Autres (1) Livres et chapitres d'ouvrages (1)

Type de document

Mémoires, Thèses et HDR (1)

Co-auteur

Date

Date

Source

Source

Mot-clé

Treatment (53) Human beings (48) Patients (47) Patients (46) dosage (39) plasma (37) Therapeutics (34) thérapie (33) Pharmacokinetics (30) pharmacocinétique (29) Methods (29) Pharmacokinetics (29) Example (29) Methods (29) modèle (28) exposition (27) dose (27) Drug monitoring (27) Management (26) Drugs (25) Population (25) Population (24) Political science (21) Blood (21) administration (20) Time (20) State, The (20) Older people (20) Administrative law (20) Administration of estates (20)

Mot-clé

Development (1) Employment (1) Variation (1) Treatment (1) Clinical pharmacology (1) Sports records (1) Signs and symbols (1) Progress (1) Prediction theory (1) Mycoses (1) Miracles (1) Medical microbiology (1) Liquids (1) Licenses (1) International organization (1) Impact (1) High pressure (Technology) (1) High pressure (Science) (1) Evidence (1) Division (1) Communicable diseases (1) Clinics (1) Candida (1) Breast (1) Blood plasma (1) Athletic ability (1) Use studies (1) Use studies (1) Technique (1) Toxicology (1)

Documents écrit par T. Buclin (96) | parle de T. Buclin (1)

Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma.
J. Tachet et al. (15 nov. 2023)
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study.
P. Thoueille et al. (27 sept. 2023)
An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup.
L. Diezi et al.
Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs.
J.K. Overbeek et al.
Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine.
V. Desfontaine et al. (15 janv. 2023)
Reproductive Safety of Trazodone After Maternal Exposure in Early Pregnancy: A Comparative ENTIS Cohort Study.
K. Dao et al. (2023)
Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective.
M. Briki et al. (2023)
From personalized to precision medicine in oncology: A model-based dosing approach to optimize achievement of imatinib target exposure.
S. Goutelle et al. (2023)
Estimating glomerular filtration rate from serum creatinine concentration in children with augmented renal clearance: all formulas are equivocal, but some are more equivocal than others.
P. André et al.
Treatment-emergent adverse events and antiseizure medication actual drug load.
T. Prétat et al.
Inhibiteurs des Janus kinases : nouvelles perspectives pour la médecine de précision ? [Janus kinase inhibitors : new perspectives for precision medicine ?]
J. Tachet et al. (19 oct. 2022)
Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children.
S. Goutelle et al. (1 oct. 2022)
Quantification of serotonin and eight of its metabolites in plasma of healthy volunteers by mass spectrometry.
P.J. Eugster et al. (10 août 2022)
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
P. Thoueille et al. (29 juil. 2022)
Development of an assay by liquid chromatography coupled to tandem mass spectrometry for thiopurines drugs in whole blood and application for their Therapeutic Drug Monitoring
N. Nguyen et al. (1 juin 2022)
Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.
P. Courlet et al.
Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing.
V. Suttels et al.
Pharmacovigilance - Vaccins à ARNm contre le Covid-19 : le point sur les effets indésirables [Pharmacovigilance - mRNA COVID-19 vaccines : current state of knowledge on their adverse effects]
V. Favre et al. (2 févr. 2022)
Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
K. Dao et al. (2 févr. 2022)
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.
P. Thoueille et al. (2 févr. 2022)
Therapeutic drug monitoring of newer generation antiseizure medications at the point of treatment failure.
P. Fluckiger et al.
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases.
P. Burckhardt et al.
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
P. Courlet et al.
Médicaments, sexe et genre [Medicines, sex and gender]
T. Buclin et al. (30 juin 2021)
Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption.
A.G. Schneider et al. (18 mai 2021)

next
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods, [and] Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
A. Pascual (2010)